AxoGen Retained Earnings (Accumulated Deficit) 2010-2024 | AXGN
AxoGen retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
| AxoGen Annual Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2024 | $-291 |
| 2023 | $-281 |
| 2022 | $-260 |
| 2021 | $-231 |
| 2020 | $-204 |
| 2019 | $-180 |
| 2018 | $-151 |
| 2017 | $-128 |
| 2016 | $-118 |
| 2015 | $-103 |
| 2014 | $-90 |
| 2013 | $-72 |
| 2012 | $-58 |
| 2011 | $-48 |
| 2010 | $-38 |
| 2009 | $-2 |
| AxoGen Quarterly Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2024-12-31 | $-291 |
| 2024-09-30 | $-292 |
| 2024-06-30 | $-290 |
| 2024-03-31 | $-288 |
| 2023-12-31 | $-281 |
| 2023-09-30 | $-277 |
| 2023-06-30 | $-273 |
| 2023-03-31 | $-267 |
| 2022-12-31 | $-260 |
| 2022-09-30 | $-254 |
| 2022-06-30 | $-250 |
| 2022-03-31 | $-242 |
| 2021-12-31 | $-231 |
| 2021-09-30 | $-225 |
| 2021-06-30 | $-218 |
| 2021-03-31 | $-210 |
| 2020-12-31 | $-204 |
| 2020-09-30 | $-198 |
| 2020-06-30 | $-196 |
| 2020-03-31 | $-188 |
| 2019-12-31 | $-180 |
| 2019-09-30 | $-173 |
| 2019-06-30 | $-167 |
| 2019-03-31 | $-160 |
| 2018-12-31 | $-151 |
| 2018-09-30 | $-145 |
| 2018-06-30 | $-141 |
| 2018-03-31 | $-134 |
| 2017-12-31 | $-128 |
| 2017-09-30 | $-126 |
| 2017-06-30 | $-124 |
| 2017-03-31 | $-122 |
| 2016-12-31 | $-118 |
| 2016-09-30 | $-112 |
| 2016-06-30 | $-110 |
| 2016-03-31 | $-107 |
| 2015-12-31 | $-103 |
| 2015-09-30 | $-100 |
| 2015-06-30 | $-97 |
| 2015-03-31 | $-94 |
| 2014-12-31 | $-90 |
| 2014-09-30 | $-84 |
| 2014-06-30 | $-80 |
| 2014-03-31 | $-77 |
| 2013-12-31 | $-72 |
| 2013-09-30 | $-68 |
| 2013-06-30 | $-65 |
| 2013-03-31 | $-61 |
| 2012-12-31 | $-58 |
| 2012-09-30 | $-54 |
| 2012-06-30 | $-52 |
| 2012-03-31 | $-51 |
| 2011-12-31 | $-48 |
| 2011-09-30 | $-46 |
| 2011-06-30 | $-2 |
| 2011-03-31 | $-2 |
| 2010-12-31 | $-38 |
| 2010-09-30 | $-1 |
| 2010-06-30 | $0 |
| 2010-03-31 | $-2 |
| 2009-12-31 | $-2 |
| 2009-09-30 | $-13 |
| 2009-06-30 | $-12 |
| 2009-03-31 | $-13 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.750B | $0.187B |
| AxoGen, Inc. engages in developing and marketing surgical solutions for peripheral nerves. The company's portfolio of products includes Avance Nerve Graft(R), AxoGuard Nerve Connector(R), AxoGuard Nerve Protector(R), Avive Soft Tissue Membrane(R), AcroVal Neurosensory & Motor Testing System(R) and AxoTouch Two-Point Discriminator(R). It operates primarily in the United States, Canada, the United Kingdom, and other European and international countries. AxoGen Inc., formerly known as AxoGen Corp., is based in FL, United States. | |||